Marksans Pharma Ltd

Dematerialisation/rematerialisation status

• Dematerialisation requests received through depository participants up to 30 September 2026 were confirmed; securities listed on exchanges.
• Certificates received for dematerialisation were mutilated and cancelled after due verification by the depository participant.
• Depository's name substituted as registered owner within 15 days of receipt.

Marksans Pharma Limited — Trading window closed from October 01, 2026 until 48 hours after the declaration of unaudited financial results for the quarter and half year ending September 30, 2026

Special Window Details

• Public notice of SEBI-mandated special window to re-lodge pre-2019 physical transfer deeds.
• Window period: February 5, 2026 to February 4, 2027.
• Applies to physical shares purchased before April 1, 2019 with deficient documents.
• If documents are in order, transfer registered and shares credited in demat mode.
• No physical certificates issued; credited shares will be in demat form.
• Shares credited will be under one-year lock-in from registration date.
• Original share certificate and pre-April 1, 2019 transfer deed.
• Proof of purchase, KYC, and latest client master list.
• Indemnity and any case-specific documents; disputes and IEPF transfers excluded.
• RTA Bigshare handles re-lodgement; contact details and emails provided.

Meeting Details

• Ashwamedh - Elara India Dialogue 2026 investor meet; 02 Sep 2026; Group, Physical; Hyatt Mumbai Santacruz East.

AGM Details

• AGM held on 27 August 2026 at 11:00 AM via VC/OAVM.
• Mode: VC/OAVM; e-voting cut-off date fixed at 20 August 2026.
• Total shareholders on cut-off: 250,569.
• Video attendees: Promoters 2; Public 59.
• Total votes cast: 29,96,58,526 shares; 426 members cast votes.

Resolutions

• Resolution 1 (Ordinary): Adoption of standalone and consolidated financial statements.
• Resolution 2 (Ordinary): Final dividend of Rs 0.90 per equity share.
• Resolution 3 (Ordinary): Appointment of Dr Sunny Sharma, retire by rotation, re-appointment.
• Resolution 4 (Special): Re-appointment of Mrs. Sandra Saldanha as Whole-time Director for 3 years; remuneration.

Dividend

• Final dividend of Rs 0.90 per equity share approved.

Director Changes

• Dr Sunny Sharma re-appointed as Director by rotation.
• Sandra Saldanha re-appointed as Whole-time Director for 3 years; remuneration approved.

Voting Results

• Resolution 1 passed: 29,66,55,847 in favour; 7,427 against.
• Resolution 2 passed: 29,72,17,862 in favour; 5,59,059 against.
• Resolution 3 passed: 29,42,25,404 in favour; 35,51,507 against.
• Resolution 4 passed: 29,66,27,255 in favour; 11,49,656 against.

AGM Details

• Date, time, and mode: 27 August 2026, 11:00 AM, via Video Conferencing.
• Mode: VC/AVM; meeting deemed to be held at the registered office for recording.
• Voting results to be announced by 28 August 2026 and posted on the website.

Resolutions

• Ordinary: Adopt standalone and consolidated financial statements for the year ended 31 March 2026.
• Ordinary: Declare dividend of Rs 0.90 per equity share.
• Ordinary: Re-appoint director retiring by rotation (Dr Sunny Sharma).
• Special: Re-appoint Mrs. Sandra Saldanha as Whole-time Director for three-year term.

Financial Performance

• Q1 FY27 revenue INR 840.8 crores, up 35.6% YoY.
• Gross profit INR 497.3 crores; gross margin 59.1% (up 138 bps YoY).
• EBITDA INR 213 crores; EBITDA margin 25.3% (vs 16.1% YoY).
• PAT INR 159.4 crores; PAT margin 18.4%.
• Operating cash flow INR 185 crores; net capex INR 33 crores.
• Free cash flow INR 152 crores.
• Working capital cycle ~132 days (vs ~159 days Q1 FY26).
• R&D spend INR 23.2 crores (2.8% of revenue).
• Cash balance INR 1,058 crores; net cash INR 1,031 crores.
• QliniQ B.V. Netherlands acquisition contributed ~INR 44 crores in Q1.
• Effective date 01-Apr-2026; consolidation in June quarter.
• North America revenue INR 377 crores; 45% of consolidated.
• UK & Europe revenue INR 356 crores; 42% of consolidated; highest quarterly for region.
• Australia & New Zealand revenue INR 88 crores; +53.7% YoY.
• Rest of World revenue INR 20 crores.

Operating / Segment Update

• Europe growth supported by QliniQ acquisition; organic UK momentum.
• Europe end-year target around INR 180 crores (EUR 14–15m).
• Germany/Netherlands acquisitions underpin Europe expansion; Ireland licensing ongoing.
• Canada product filings underway; Europe driving incremental growth.

Balance Sheet and Cash Flow

• End-Q1 cash INR 1,058 crores; net cash INR 1,031 crores.
• Operating cash flow INR 185 crores; free cash flow INR 152 crores.
• Working capital cycle ~132 days.

Projects and Capex

• Goa unit progressing; Teva facility targeted INR 80 crores revenue; current ~INR 50 crores.
• Possible new manufacturing unit in India; timing not fixed.
• Goa/Teva capex progress aligns with 3–5 year plan.

Outlook and Guidance

• FY27 revenue growth guidance: 15% to 20%.
• FY27 EBITDA margin guidance: 20% to 21%.
• Europe FY27 revenue around INR 180 crores (EUR 14–15m).
• Q2 revenue expected to be higher than Q1; Q3 strongest.

Q&A Takeaways

• QliniQ guidance: INR 150–175 crores revenue for FY27; consolidation effective Apr 1, 2026.
• Europe expansion: Germany revenue expected early Q3; Ireland licensing delays noted.
• US strategy remains important; potential capacity expansion discussed; timing uncertain.
• Gross margin comfortably guided around 55–56% under current geopolitics and costs.
• Acquisition appetite remains active in Europe; resources on balance sheet to fuel inorganic growth.
• R&D focus on product differentiation; Europe mix tilting toward Rx (80–85%) vs OTC.

Meeting Details

• Date: August 13, 2026; investor/analyst conference call on Q1FY27 results.
• Audio recording of the call uploaded to the company website.

Purpose

• Inform investors that Q1FY27 investor call audio is now available.